P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

April 2002

Features

Clinical Update: Oncology Pharmaceuticals

Dr. Goldenberg presents recent studies on various cancers and the implications of new and existing therapies.
Marvin M. Goldenberg, PhD

Drug Shortages (4-Part Series)

Part 3: ISMP Drug Shortages Survey: Proactive Guidelines to Safely Manage Scarce Supplies

The results of the ISMP’s recent national survey on drug shortages are discussed, along with guidelines on how to handle drug shortages.
Matthew Grissinger, RPh

Pharmaceutical Spotlight: Recombinant Human Activated Protein C (rhAPC) or Drotrecogin Alfa (Activated)

This article focuses on the revolutionary new drug that combats a highly complicated disease: sepsis.
Michelle Leady, PharmD, Michael Kraft PharmD, and Cesar Alaniz, PharmD

Proton Pump Inhibitor Attitudes and Usage: A Patient Survey

Despite the widely held belief that therapy with PPIs renders patients asymptomatic, breakthrough symptoms are common.
Malcom Robinson, MD and Kimberly Shaw, BA

Measuring Patients’ Health-Related Quality of Life: Practical Considerations for Implementing an Outcomes Management Program

Patient self-administered questionnaires could help determine health-related quality of life in outcomes management.
Jennifer Lofland, PharmD

Guest Commentary

The FDA and a Plea for Placebos

Is a placebo-controlled trial ethical if an effective treatment has already been established? The author discusses the issue with Robert Temple, MD.
Miriam Reisman

Departments

Editorial

Sepsis Segue

Editor-in-Chief David B. Nash discusses what is needed for an effective “Sepsis Segue.”
David Nash, MD, MBA

Prescription Washington

The FTC and Patent Wars

Stephen Barlas

Newsletter Exchange